LAUSR

AGREE, Appraisal of guidelines for research and evaluation; ALT, alanine aminotransferase; anti-HCV, antibody to hepatitis C; APRI, aminotransferaseto-platelet ratio index; AST, aspartate aminotransferase; ASV, asunaprevir; AUC, area under the curve; /r, /ritonavir; CTP, Child-Pugh Turcotte; eGFR, estimated glomerular filtration rate; DAA, direct-acting antivirals; DCV, daclatasvir; DDI, drug–drug interactions; EBR/GZR, elbasvir/grazoprevir; ESRD, end-stage renal disease; ETR, end-of treatment response; FIB-4, fibrosis-4 score; GFR, glomerular filtration rate; G/P, glecaprevir/pibrentasvir; GRADE, grading of recommendations, assessment, development and evaluation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug user; KASL, Korean Association for the Study of the Liver; LC, liver cirrhosis; LED/SOF, ledipasvir/sofosbuvir; MELD, model for end-stage liver disease; MSM, man who have sex with man; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NS, nonstructural protein; NS3, nonstructural protein 3; NS5A, nonstructural protein 5A; OATP, organic anion-transporting polypeptide; Opr+D, ombitasvir/paritaprevir/ritonavir and dasabuvir; PCR, polymerase chain reaction; PegIFN, peginterferon; P-gp, P-glycoprotein; PI, protease inhibitor; PR, peg interferon-alpha + ribavirin therapy; PWID, people who inject drugs; R*, ribavirin started from 600 mg/d; R, weight-based ribavirin; RASs, resistanceassociated substitutions; SOF, sofosbuvir; SOF/VEL, sofosbuvir/velpatasvir; SOF/ VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir; SVR, sustained virologic response rate; TDF, tenofovir disoproxil fumarate Corresponding author : The Korean Association for the Study of the Liver (KASL) (Committee Chair: Jong Eun Yeon) Room A1210 MapoTrapalace, 53 Mapo-daero, Mapo-gu, Seoul 04158, Korea Tel: +82-2-703-0051, Fax: +82-2-703-0071 E-mail: [email protected]